VivoSeq
Oncology

Marginal Zone B-Cell Lymphoma

16

Pipeline Programs↗

1

Active Trials↗

12

Companies Involved↗

Marginal Zone B-Cell Lymphoma is an emerging landscape with 16 programs across 12 companies. The most active players are Incyte, Novartis, Roche. 7 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Incyte logo

Incyte

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2Roche logo

Roche

2 programs

Phase 3B

Beijing InnoCare Pharma Tech Co., Ltd.

1 program

Phase 3Otsuka logo

Otsuka

1 program

ApprovedB

BeOne Medicines

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

71%

Small molecule

12 of 17 classified programs — the dominant modality here.

29%ALL OTHERSMonoclonal antibody529%

Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 100% of 17 pipeline programs.

Analysis

Trial Status

6

clinical trials

Completed4 · 67%
Unknown status1 · 17%
Not yet recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma
Not yet recruiting·HHenan Cancer Hospital·N/A·NCT07492407·131 enrolled
Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
Completed·SSeoul National University Hospital·Phase 2·NCT02433795·27 enrolled
Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)
Completed·IInternational Extranodal Lymphoma Study Group (IELSG)·Phase 2·NCT01164267·30 enrolled
Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)
Completed·—·Phase 2·NCT01213095·48 enrolled
Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)
Completed·—·Phase 2·NCT01068392·42 enrolled
131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma
Unknown status·KKorea Cancer Center Hospital·Phase 2·NCT01678404·28 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)